	US 11,723,911 B2
	Treatment of demyelinating diseases
Claudia Mattern, Emmetten (CH); Elisabeth Traiffort, Paris (FR); and Michael Schumacher, Kemlin-Bicêtre (FR)
Assigned to M ET P PHARMA AG, Emmetten (CH)
Filed by M ET P PHARMA AG, Emmetten (CH)
Filed on Jan. 25, 2021, as Appl. No. 17/157,337.
Application 17/157,337 is a continuation of application No. 16/815,969, filed on Mar. 11, 2020, granted, now 10,898,495.
Application 16/815,969 is a continuation of application No. 16/506,830, filed on Jul. 9, 2019, granted, now 10,596,181.
Application 16/506,830 is a continuation in part of application No. PCT/IB2019/050198, filed on Jan. 10, 2019.
Claims priority of provisional application 62/616,173, filed on Jan. 11, 2018.
Prior Publication US 2021/0283143 A1, Sep. 16, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/56 (2006.01); A61K 31/381 (2006.01); A61K 31/565 (2006.01); A61K 31/4545 (2006.01); A61K 31/568 (2006.01); A61K 9/00 (2006.01); A61K 31/4436 (2006.01); A61K 31/506 (2006.01)

CPC A61K 31/568 (2013.01) [A61K 9/0043 (2013.01); A61K 31/4436 (2013.01); A61K 31/506 (2013.01)]

20 Claims

1. A method of promoting remyelination in a subject in need thereof, comprising administering to the subject an effective amount of a steroid hormone and a Smoothened agonist (Smo agonist).